[Monoclonal anti-D immunoglobulin for prevention of hemolytic disease of the newborn].
Stable human-mouse heterohybridoma producing human monoclonal anti-D IgG1 has been derived by fusing Epstein-Barr virus (EBV) transformed human immune lymphocytes with mouse myeloma. The absence of EBV DNA in heterohybridoma was demonstrated by the polymerase chain reaction. The antibody was purified by affinity chromatography on protein A Sepharose and tested for sterility, pyrogenicity and toxicity according to the Pharmacopoeia XI and the ability to clear from circulation RhoD-positive red cells. The time of clearance of sensitized RBC was about 3 hrs. Since it is believed to be an association between the rate of RBC clearance by anti-D and the ability of the antibody to suppress the immunization, the monoclonal immunoglobulin may prove suitable for immunoprophylaxis of RhD hemolytic disease.
Olovnikova
N I
NI
Belkina
E V
EV
Berkovskiĭ
A L
AL
Lemeneva
L N
LN
Nikolaeva
T L
TL
Chertkov
I L
IL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007231:Infant, Newborn; D051379:Mice; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018029:Rho(D) Immune Globulin
Monoklonal'nyĭ anti-D immunoglobulin dlia profilaktiki gemoliticheskoĭ bolezni novorozhdennykh.